Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
Posted on: Friday, 13 March 2009, 12:00 CDT
First launched in 2006, TDI is designed exclusively to support and bolster industry-focused efforts on Parkinson's research as part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies -- thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.
Years of basic research in cell-based studies and animal models have uncovered numerous promising biological targets that show initial promise to impact the symptoms and progression of Parkinson's disease. But translating these fundamental discoveries into practical treatments requires focused and concerted effort to identify and optimize realistic strategies for eventual human testing.
Under the 2009 TDI program, MJFF primarily seeks to support pre-clinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and/or improving treatment of symptoms above and beyond current standards of care. Proposals must focus on key and critical pre-clinical studies necessary for developing, optimizing and evaluating therapeutic strategies that, if successful, can move into human testing.
The first three years of TDI were enthusiastically received by industry researchers. To date the Foundation has awarded nearly
About The Michael J. Fox Foundation
The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease through an aggressively funded research agenda. To date, the Foundation has funded nearly
SOURCE Michael J. Fox Foundation
Source: PR Newswire
Related Articles
- Philanthropists, Medical Research Foundations, and Industry Leaders Gather in New York for Inaugural Partnering for Cures Meeting
- Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
- Fisher Center for Alzheimer's Research Foundation Names Kent Karosen to Serve as President and CEO
- Reminder: Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
- Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium
- Bayhill Therapeutics and the Juvenile Diabetes Research Foundation Announce Research Collaboration for the Clinical Development of a Novel Immunotherapeutic DNA Vaccine for Type 1 Diabetes
- Research Foundation for Tick-Borne Diseases to Fund Studies of Neurological and Immunological Mechanisms in Lyme Disease
- Ciphergen and Ohio State University Research Foundation Sign Collaborative Agreement to Develop Diagnostic Test for Blood Disorder
- Juvenile Diabetes Research Foundation Partners With Stemnion
- Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology From Wisconsin Alumni Research Foundation (WARF)
User Comments (0)


RSS Feeds